NCT03754933View on ClinicalTrials.gov

Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 11, 2019

Primary Completion Date

December 29, 2023

Study Completion Date

December 31, 2024

Conditions
Recurrent Head and Neck Cancer
Interventions
BIOLOGICAL

Ad/PNP

Ad/PNP is a replication defective adenoviral vector expressing E. coli Purine Nucleoside Phosphorylase

DRUG

Fludarabine Phosphate

Fludarabine phosphate is an anticancer agent currently used for treatment of patients with chronic lymphocytic leukemia.

Trial Locations (3)

19107

Thomas Jefferson University, Philadelphia

30322

Winship Cancer Institute - Emory University School of Medicine, Atlanta

94305

Stanford University, Stanford

All Listed Sponsors
collaborator

Stanford University

OTHER

collaborator

Emory University

OTHER

collaborator

Thomas Jefferson University

OTHER

lead

GeoVax, Inc.

INDUSTRY

NCT03754933 - Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer | Biotech Hunter | Biotech Hunter